In Re Telik, Inc. Securities Litigation

576 F. Supp. 2d 570, 2008 U.S. Dist. LEXIS 69197, 2008 WL 4198516
CourtDistrict Court, S.D. New York
DecidedSeptember 10, 2008
Docket07 Civ. 4819(CM)
StatusPublished
Cited by47 cases

This text of 576 F. Supp. 2d 570 (In Re Telik, Inc. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Telik, Inc. Securities Litigation, 576 F. Supp. 2d 570, 2008 U.S. Dist. LEXIS 69197, 2008 WL 4198516 (S.D.N.Y. 2008).

Opinion

DECISION AND ORDER APPROVING THE SETTLEMENT, CERTIFYING THE CLASS FOR SETTLEMENT PURPOSES, APPROVING THE PLAN OF ALLOCATION OF THE NET SETTLEMENT FUND, DISALLOWING THE OBJECTIONS, AND AWARDING ATTORNEYS’ FEES

McMAHON, District Judge:

Preliminary Statement

The core allegation in the Complaint is that the Telik Defendants 1 received data about Phase 3 clinical tests on Telik’s leading new drug candidate, TELCYTA, on a “rolling basis” from the “interim looks” that Defendants Wick and Buttita stated were built into the study. Plaintiffs alleged that, based on their receipt of negative interim data concerning the TELCY-TA Phase 3 trials, the Telik Defendants knew that their contemporaneous positive statements concerning the Phase 2 and 3 trial results were materially misleading. In addition, Plaintiffs alleged the Telik Defendants knew that an increasing number of participants in the lung cancer arm of the tests, eventually totaling 25% of the enrolled patients, were prematurely withdrawn from the study, compromising the data and rendering it unusable for FDA purposes.

However, Lead Counsel learned during the settlement discussions and mediation, and later confirmed through discovery, that the Telik Defendants were actually blinded to all substantive data during the conduct of the Phase 3 trials. The “interim looks” referenced by Defendants Wick and Buttita were, in fact, periodic reports to the independent Data Monitoring Committees overseeing those tests — not to Te-lik. (See Dkt. #72, 8/29/2008 MacFall Deck ¶¶ 3, 28-29.) Lead Counsel reviewed thousands of pages of documents, including the FDA-approved Protocols governing the tests and the charters of the independent DMCs overseeing each of the tests, which demonstrated that the Telik Defendants were, in fact, blinded to all substantive data from the Phase 3 tests. This was further corroborated by the testimony of Defendant Telik CFO Cynthia Buttita and Telik Chief Medical Officer Dr. Gail Brown.

Plaintiffs believe that they could have successfully amended their claims, based on the foregoing, to allege that the Telik Defendants’ statements concerning the interim looks were, themselves, materially *574 false and misleading because the Phase 3 tests were blinded. Plaintiffs, however, were mindful that even such amended claims might be susceptible to substantial defenses with respect to scienter and loss causation. The Settlement presents an excellent result for the investor Class.

Plaintiffs estimate that the Settlement represents recovery of approximately 25% of the recoverable damages that Plaintiffs could have proved if this action went to trial. While Plaintiffs’ damages expert estimated the aggregate loss of market value subsequent to relevant disclosures about TELCYTA at $449 million, he opined that much of this market loss is attributable to market forces. Specifically, most of the market loss represents investors’ reaction to the fact that the Company’s primary new drug candidate, TELCYTA, failed FDA testing, as opposed to the disclosure of any fraud. 2 This should come as little or no surprise to anyone.

To assess the extent to which the loss in market value was attributable to market forces as opposed to fraud, Lead Counsel analyzed 10 comparable biotechnology companies. These companies were selected because each had a primary drug candidate that failed Phase 3 FDA testing, no allegations of fraud were made, and no securities fraud litigation was filed, in connection with such failure. (See MacFall Declaration ¶ 33 and Ex. C. 3 ) These companies lost between 40% and 87.83% of their market value, for an average loss of 67.21% of market value, upon disclosure of the Phase 3 test failures.

Here, Telik lost 71.77% of its market value upon the corrective disclosures of December 26, 2006, and June 3 and 4, 2007. 4 Thus, assuming that Plaintiffs believe that they could establish that the maximum recoverable damages in this litigation are approximately $20.47 million, or 4.56% of Telik’s aggregate market value loss, the $5 million cash recovery provided by the proposed Settlement represents approximately 25% of the maximum recoverable damages that Lead Plaintiff believes it could establish at trial.

Pursuant to the Preliminary Order, copies of the Court-approved Notice of Pen-dency and Proposed Settlement of Class Action (“Notice”) were sent to over 54,000 Class members, and a Summary Notice was published in the national edition of The Wall Street Journal on June 20, 2008. In the Notice, Class members were advised that the deadline for objections was August 8, 2008. (See Keough Aff., Mac-Fall Deck Ex. D, ¶¶ 7, 8.)

To date, only three Class members have objected to the Settlement and three Class members have opted to exclude themselves *575 from the Settlement. The percentage of objecting Class members is below .006%.

Lead Counsel, who are very experienced in prosecuting securities class action litigation, have concluded that the Settlement is in the best interests of the Class.

I. STANDARDS FOR APPROVAL OF CLASS ACTION SETTLEMENTS

There is a “strong judicial policy in favor of settlements, particularly in the class action context.” In re Paine Webber Ltd. P’ships Litig., 147 F.3d 132, 138(2d Cir.1998). “Settlement approval is within the Court’s discretion, which ‘should be exercised in light of the general judicial policy favoring settlement.’ ” In re EVCI Career Colleges Holdings Corp. Sec. Litig., No. 05 Civ. 10240(CM), 2007 WL 2230177, at *3 (S.D.N.Y. July 27, 2007) (citation omitted); accord Maley v. Del Global Techs. Corp., 186 F.Supp.2d 358, 361 (S.D.N.Y.2002); In re Am. Bank Note Holographics, 127 F.Supp.2d 418, 424 (S.D.N.Y.2001). As this Court has stated: “In its exercise of that discretion, the Court must engage in a careful balancing act: ‘The Court must eschew any rubber stamp approval in favor of an independent evaluation, yet, at the same time, it must stop short of the detailed and thorough investigation that it would undertake if it were actually trying the case.’” Am. Bank, 127 F.Supp.2d at 424 (citing City of Detroit v. Grinnell Corp., 495 F.2d 448, 462 (2d Cir.1974)).

Courts determine the fairness of a settlement by looking both at the terms of the settlement and the negotiation process leading up to it. See Wal-Mart Stores, Inc., v. Visa U.S.A., Inc., 396 F.3d 96 at 116 (2d Cir.2005) (citing D’Amato v. Deutsche Bank, 236 F.3d 78, 85 (2d Cir.2001)). With respect to process, a class action settlement enjoys a “presumption of correctness” where it is the product of arm’s-length negotiations conducted by experienced, capable counsel. In re Union Carbide Corp. Consumer Prods. Bus. Sec. Litig., 718 F.Supp. 1099, 1103 (S.D.N.Y.1989) (Brieant, J.) (citing

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
576 F. Supp. 2d 570, 2008 U.S. Dist. LEXIS 69197, 2008 WL 4198516, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-telik-inc-securities-litigation-nysd-2008.